Apellis Pharmaceuticals (APLS) Earnings Date & Reports

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more

Industry: #Medical Distributors

Get AI intraday signals

A.I. Advisor

published Earnings

APLS is expected to report earnings to rise 17.93% to -34 cents per share on May 01

Apellis Pharmaceuticals APLS Stock Earnings Reports

Q1'25

Est.

$-0.34

Q4'24

Beat

by $0.08

Q3'24

Missed

by $0.17

Q2'24

Beat

by $0.01

Q1'24

Missed

by $0.07

The last earnings report on February 28 showed earnings per share of -28 cents, beating the estimate of -37 cents. With 214.30K shares outstanding, the current market capitalization sits at 2.18B.

View a ticker or compare two or three

Compare

APLS